Short Interest in Biofrontera Inc. (NASDAQ:BFRI) Grows By 675.7%

Biofrontera Inc. (NASDAQ:BFRI) saw a significant growth in short interest during the month of August. As of August 31st, there was short interest totaling 255,272 shares, a growth of 675.7% from the August 15th total of 32,907 shares. Based on an average trading volume of 674,900 shares, the short-interest ratio is presently 0.4 days. Approximately 1.9% of the shares of the stock are short sold.

Hedge Funds Weigh In On Biofrontera

An institutional investor recently raised its position in Biofrontera stock. Geode Capital Management LLC increased its position in shares of Biofrontera Inc. (NASDAQ:BFRI) by 54.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 65,677 shares of the company’s stock after buying an additional 23,074 shares during the quarter. Geode Capital Management LLC owned 0.56% of Biofrontera worth $37,000 as of its most recent SEC filing. 10.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

BFRI has been the topic of a number of research analyst reports. Wall Street Zen upgraded Biofrontera to a “hold” rating in a research report on Saturday, July 18th. Weiss Ratings upgraded Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Finally, Zacks Research raised Biofrontera from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Biofrontera Price Performance

Biofrontera stock opened at $1.46 on Friday. The firm has a market capitalization of $21.68 million, a P/E ratio of -3.24 and a beta of 0.83. The business has a 50-day moving average of $1.29 and a 200-day moving average of $1.07. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.78. Biofrontera has a 1 year low of $0.55 and a 1 year high of $1.66.

Biofrontera (NASDAQ:BFRI) last issued its earnings results on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.05. Biofrontera had a negative net margin of 13.78% and a negative return on equity of 145.81%. The firm had revenue of $12.00 million during the quarter, compared to the consensus estimate of $9.50 million. On average, equities analysts anticipate that Biofrontera will post -0.6 EPS for the current year.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.